Last reviewed · How we verify
An'ningpai
An'ningpai is a traditional Chinese medicine formulation used to treat pulmonary conditions, likely working through anti-inflammatory and bronchodilatory mechanisms.
An'ningpai is a traditional Chinese medicine formulation used to treat pulmonary conditions, likely working through anti-inflammatory and bronchodilatory mechanisms. Used for Pulmonary/respiratory conditions (specific indications not clearly documented in available sources).
At a glance
| Generic name | An'ningpai |
|---|---|
| Also known as | Expectorant |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
An'ningpai appears to be a herbal or traditional Chinese medicine product developed and marketed by Shanghai Pulmonary Hospital for respiratory diseases. The exact molecular mechanism is not well-documented in Western pharmaceutical literature, but traditional formulations for pulmonary conditions typically work through reducing airway inflammation, promoting mucus clearance, and improving respiratory function.
Approved indications
- Pulmonary/respiratory conditions (specific indications not clearly documented in available sources)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- An'ningpai CI brief — competitive landscape report
- An'ningpai updates RSS · CI watch RSS
- Shanghai Pulmonary Hospital, Shanghai, China portfolio CI